The Role of Aldose Reductase in Polyol Pathway: An Emerging Pharmacological Target in Diabetic Complications and Associated Morbidities.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and preclinical findings without systematic search methods.
PubMed 37649296 · doi:10.2174/1389201025666230830125147
What was done
Narrative review describing the biochemical role of aldose reductase in the polyol pathway, its involvement in diabetic complications, and preclinical evidence regarding its inhibition in diabetes-associated inflammatory disorders.
What was found
The abstract reports no quantitative data or numerical findings. It details mechanisms wherein aldose reductase uses NADPH to convert glucose to sorbitol, leading to sorbitol accumulation, osmotic disturbance, reactive oxygen species generation, and NF-kB activation in diabetic tissues (heart, neurons, kidneys, eyes, and vasculature). It also notes that preclinical studies have observed aldose reductase inhibitors reducing inflammation-related conditions such as asthma, sepsis, and colon cancer.
Why it matters
Synthesizes mechanistic rationale for targeting aldose reductase to prevent diabetic microvascular and macrovascular complications, as well as broader inflammatory comorbidities.
Limits
The abstract provides no human clinical trial data, no systematic search methodology, no quantitative effect sizes, and no details on the efficacy or safety profiles of specific pharmacological inhibitors.
Cited by
- supports In diabetic retinopathies and nephropathies, excess intracellular glucose is diverted into the sorbitol pathway, where sorbitol accumulation creates an osmotic gradient causing hydropic degeneration and cell rupture.